PerpEquities

GenScript Biotech Corporation (GENSCRIPT) financials

HKSE · Healthcare · Biotechnology · 6,135 employees · CEO Weihui Shao

Price
$3.54 0.0%
Market cap
$7.97B
Enterprise value
$8B Data as of 2026-11-21
Last report
Q2 '26 filed 2026-06-30
Next report
2027-03-24
Revenue (TTM)$844M+1.9% vs a year agoLast 2 half-years; bars = each half-year
Operating margin (TTM)14.9%-6.8 pp vs a year agoOperating income $126M
Net income (TTM)-$636M-120.5% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$50.3M-74.9% vs a year agoCapex $99.3M
Diluted EPS (TTM)-$0.29-3,419.5% vs a year agoSum of the last 2 half-years
Net cash$577M+481.0% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
$7.97B
Updated 11m ago
Revenue
$844M
Trailing 12 months
Revenue growth
-7%
FY2026 consensus
Profit margin
-75.4%
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
9.4×
Price / sales, TTM
EV / EBITDA
39.0×
TTM
Free cash flow
$50.3M
Trailing 12 months
Net income
-$636M
Trailing 12 months
Revenue estimate
$894M
FY2026 consensus
Earnings
2027-03-24
Revenue est. $496M · Updated 11m ago
Dividend
HK$0.01
Per payment · 2017-06-05

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Revenue growth slowing: -22.3% year on yearQ2 '26 revenue $403M, against an average of 16.6% over the four half-years before.
  • Operating margin 14.9% (TTM), -6.8 pp on a year agoOperating income grew -30.0% while revenue grew 1.9%.
  • Capex 11.8% of revenue (a year ago 3.9%)$99.3M invested in the last 2 half-years (+209.1% on a year earlier). Free cash flow $50.3M.
  • Returned $225M to shareholders = 447.6% of free cash flowBuybacks $225M (a year earlier $0), dividends $0, stock-based pay $5.22M (TTM). More than the free cash flow: paid from cash or debt.
  • Diluted share count up 1.4% in a year2.19B diluted shares in Q2 '26, 2.16B a year earlier.
  • Net cash $577MCash + short-term investments $831M, debt incl. leases $255M; a year ago net debt $151M.

Last quarter: Q2 '26

Quarter ended 2026-06-30. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q2 '26Year agoChange
Revenue$403M$519M-22.3%
Gross margin51.1%61.8%-10.7 pp
Operating income$49.4M$179M-72.4%
Operating margin12.3%34.5%-22.3 pp
Net income-$129M-$25.5M-406.8%
Diluted EPS-$0.06-$0.02-171.3%
Operating cash flow$56.7M$233M-75.6%
Capex$47.6M$32.1M+48.1%
Free cash flow$9.1M$200M-95.5%
R&D$39.3M$31.3M+25.6%
Stock-based compensation$0$9.58M-100.0%

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 2 half-years

cash flow statement
Operating cash flow
$150M
Capex
-$99.3M
Buybacks
-$225M
Dividends
$0
Acquisitions
-$8.32M
Net debt issued
$78M
Stock-based compensation
$5.22M
Free cash flow
$50.3M
Returned to shareholders / FCF
447.6%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)–12.7× 1 of 5 years12.7× – 12.7×
EV / EBITDA39.0×31.4× 3 of 5 years10.8× – 43.2×
EV / Sales9.5×8.6×3.7× – 16.2×
Price / FCF158.4×14.3× 1 of 5 years14.3× – 14.3×
Price / Book2.0×4.1×0.6× – 8.6×
FCF yield0.6%-2.4%-8.3% – 7.0%
Return on invested capital2.9%-7.4%-22.5% – 5.5%
Return on equity-16.2%-1.7%-34.3% – 68.5%

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal yearRevenueGrowthEPSGrowthP/E at today's priceAnalysts (EPS)
FY2026$894M-6.8%$0.01+105.2%–3
FY2027$1.2B+34.1%$0.09+622.4%–3
FY2028$1.52B+26.5%$0.17+76.2%–4

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-21